The findings indicated that in HCC patients who had previously received immune checkpoint inhibitors and multi-kinase tyrosine kinase inhibitors, and showed FGF19 overexpression, Irpagratinib achieved an ORR of 44.8%, a median response duration of 7.4 months, and a median progression-free survival of 5.5 months 243, 244. The gene discussed is FGF19; the disease is hepatocellular carcinoma.